Decoding cancer therapy resistance through advanced 3D organoid systems

Precision oncology still faces low clinical translation rates. This is largely because two-dimensional (2D) culture systems cannot reproduce tumor heterogeneity and microenvironmental stress. Here, we review the applications of 3D cancer models, including scaffold-free spheroids, patient-derived organoids (PDOs) biobanks, and microphysiological systems (MPSs), in drug resistance modeling and personalized therapy. These platforms effectively model metabolic gradients, lineage plasticity, and immunological features within the tumor microenvironment (TME), thereby bridging the genotype-phenotype gap. They also capture physical immune exclusion, T cell exhaustion, and antigen presentation to facilitate the evaluation of immunotherapies. Last, we discuss key translational bottlenecks such as standardization and throughput, proposing the integration of advanced biomanufacturing, artificial intelligence (AI)–driven phenomics, and computational modeling to develop 3D cancer platforms into clinical predictive systems for optimizing precision treatment strategies.

Authors

Institutions

Publication Details

Journal
Science Advances
Published
2026-11-13
DOI
https://doi.org/10.1126/sciadv.aei0485
Primary Topic
3D Printing in Biomedical Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Decoding cancer therapy resistance through advanced 3D organoid systems

Zhongwei Zhang, Yupei Zhang, Shugang Qin, Yan Chen et al.
Science Advances
3D Printing in Biomedical Research
article

Decoding cancer therapy resistance through advanced 3D organoid systems

Zhongwei Zhang, Yupei Zhang, Shugang Qin, Yan Chen, Jie Wang, Wan Xu, Rui Ye
article en

Abstract

Precision oncology still faces low clinical translation rates. This is largely because two-dimensional (2D) culture systems cannot reproduce tumor heterogeneity and microenvironmental stress. Here, we review the applications of 3D cancer models, including scaffold-free spheroids, patient-derived organoids (PDOs) biobanks, and microphysiological systems (MPSs), in drug resistance modeling and personalized therapy. These platforms effectively model metabolic gradients, lineage plasticity, and immunological features within the tumor microenvironment (TME), thereby bridging the genotype-phenotype gap. They also capture physical immune exclusion, T cell exhaustion, and antigen presentation to facilitate the evaluation of immunotherapies. Last, we discuss key translational bottlenecks such as standardization and throughput, proposing the integration of advanced biomanufacturing, artificial intelligence (AI)–driven phenomics, and computational modeling to develop 3D cancer platforms into clinical predictive systems for optimizing precision treatment strategies.

Science AdvancesVol. 12(46)
University of Electronic Science and Technology of China (CN), Sichuan University (CN), West China Medical Center of Sichuan University (CN), West China Hospital of Sichuan University (CN), Sichuan Cancer Hospital (CN), Hanzhong Central Hospital (CN), State Key Laboratory of Biotherapy (CN), State Key Laboratory of Oral Diseases (CN)
3D Printing in Biomedical Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon